Evidence map›Paper›PMID 29046453›Full record

ArticleJournal of virology2018

Murine Hepatitis Virus nsp14 Exoribonuclease Activity Is Required for Resistance to Innate Immunity.

James Brett Case, Yize Li, Ruth Elliott, Xiaotao Lu, Kevin W Graepel, Nicole R Sexton, Everett Clinton Smith, Susan R Weiss, Mark R Denison

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 1 pooled it
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. SARS-CoV-2 nsp15 endoribonuclease antagonizes dsRNA-induced antiviral signaling.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

James Brett CaseDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Yize LiDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Ruth ElliottDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Xiaotao LuDepartment of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Kevin W GraepelDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Nicole R SextonDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Everett Clinton SmithDepartment of Biology, The University of the South, Sewanee, Tennessee, USA.
Susan R WeissDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Mark R DenisonDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA mark.denison@vanderbilt.edu.
Vanderbilt University Medical Center · USUniversity of Pennsylvania · USSewanee: The University of the South · US

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM007347 · NIGMS · VANDERBILT UNIVERSITY · PI WILLIAMS, CHRISTOPHER S. · 1985 to 2023
$26.3M
Control of Viral Pathogenesis by Regulation of 2-5A LevelsR01AI104887 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI SILVERMAN, ROBERT H., WEISS, SUSAN R · 2013 to 2023
$7.6M
TRAINING GRANT IN MECHANISMS OF VASCULAR DISEASET32HL007751 · NHLBI · VANDERBILT UNIVERSITY · PI BOCK, PAUL E · 1994 to 2014
$6.6M
Determinants of Coronavirus Fidelity in Replication and PathogenesisR01AI108197 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BARIC, RALPH S, DENISON, MARK R · 2013 to 2022
$6.5M
Murine coronavirus neurovirulence: role of type I interferon responseR01NS081008 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI WEISS, SUSAN R · 2012 to 2016
$1.7M
Roles of replication fidelity in viral RNA synthesis, population diversity, and overall fitness of coronavirusesF30AI129229 · NIAID · VANDERBILT UNIVERSITY · PI GRAEPEL, KEVIN WHITTLE · 2017 to 2020
$113k
NHLBI NIH HHS T32 HL007751NIAID NIH HHS F30 AI129229NIAID NIH HHS R01 AI104887NIAID NIH HHS R01 AI108197NIGMS NIH HHS T32 GM007347NINDS NIH HHS R01 NS081008
6 · The paper itself

Abstract

Coronaviruses (CoVs) are positive-sense RNA viruses that infect numerous mammalian and avian species and are capable of causing severe and lethal disease in humans. CoVs encode several innate immune antagonists that counteract the host innate immune response to facilitate efficient viral replication. CoV nonstructural protein 14 (nsp14) encodes 3'-to-5' exoribonuclease activity (ExoN), which performs a proofreading function and is required for high-fidelity replication. Outside of the order

Indexed as

Immunity, InnateAnimalsAntiviral AgentsExoribonucleasesGenome, ViralInterferon-betaMiceMurine hepatitis virusMutagenesisMutationRNA, ViralViral Nonstructural ProteinsVirus ReplicationAntiviral AgentsExoribonucleasesInterferon-betaRNA, ViralViral Nonstructural ProteinscoronavirusExoNexoribonucleaseinnate immunityinterferonMHV

Identifiers

PMID29046453
PMCPMC5730787
OpenAlexW2952414199

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.